GlassScriptPhysician profile
Deepthi Busayavalasa
NPI 1174971469
$21,769.65
in general payments reported to CMS, 2019-2025
71 companies · $9,650 in 2025
The $9,650 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $123 · 2021: $329 · 2022: $752 · 2023: $4,451 · 2024: $6,172 · 2025: $9,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,560 · Consulting Fee: $6,450 · Travel and Lodging: $2,018 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,560.05 |
| Consulting Fee | $6,450.00 |
| Travel and Lodging | $2,018.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $244.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,808.12 | 2023-2025 | Truqap, Enhertu, Imfinzi |
| Avyxa Pharma, LLC | $4,521.02 | 2025 | |
| Seagen INC. | $1,717.48 | 2021-2023 | Padcev, Tukysa |
| Genentech USA, INC. | $598.89 | 2019-2025 | Polivy, Columvi, Tecentriq |
| Daiichi Sankyo INC. | $568.10 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $553.36 | 2023-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $545.37 | 2019-2025 | Talvey, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $483.30 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Gilead Sciences, INC. | $466.68 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $388.24 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $358.42 | 2019-2024 | Vyloy, Padcev, Xtandi |
| Pfizer INC. | $343.04 | 2023-2025 | |
| Incyte Corporation | $338.97 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Merck Sharp & Dohme LLC | $321.62 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $319.30 | 2023-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $283.47 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Genentech, INC. | $262.14 | 2023-2024 | Tecentriq, Lunsumio, Alecensa |
| Genzyme Corporation | $254.03 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $223.89 | 2023 | Clonoseq |
| Sobi, INC | $220.83 | 2024 | |
| Adc Therapeutics America, INC. | $214.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $195.49 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $165.00 | 2023-2025 | Fruzaqla, Iclusig, Alunbrig |
| Lilly USA, LLC | $160.52 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $150.47 | 2020-2023 | Tazverik |
| Karyopharm Therapeutics INC. | $145.58 | 2022-2025 | Xpovio |
| Array Biopharma INC | $133.79 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Emd Serono, INC. | $118.73 | 2023-2025 | Bavencio |
| Regeneron Pharmaceuticals, INC. | $116.11 | 2023 | Libtayo |
| Abbvie INC. | $115.93 | 2024-2025 | |
| Stemline Therapeutics INC. | $114.13 | 2023-2025 | Orserdu, Elzonris |
| Taiho Oncology, INC. | $103.66 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.18 | 2022-2025 | |
| Beigene USA, INC. | $90.16 | 2021-2024 | Tevimbra, Brukinsa |
| Astellas Pharma Global Development | $85.71 | 2023 | Xospata |
| Recordati_rare_diseases_inc. | $75.36 | 2025 | Enjaymo, Sylvant |
| Tempus Ai, INC | $69.97 | 2024-2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $60.87 | 2023-2024 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.69 | 2022-2024 | Gilotrif |
| Genmab U.S., INC. | $58.11 | 2023-2024 | Epkinly |
| Blueprint Medicines Corporation | $54.09 | 2022-2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $54.08 | 2023-2025 | |
| Amgen INC. | $52.58 | 2019-2023 | Kyprolis |
| Tersera Therapeutics LLC | $51.00 | 2024 | Zoladex |
| Emmaus Medical, INC. | $50.97 | 2023 | Endari |
| Geron Corporation | $45.23 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $44.02 | 2024-2025 | Ogsiveo |
| Puma Biotechnology, INC. | $40.12 | 2023-2024 | |
| Exelixis INC. | $38.87 | 2025 | Cabometyx |
| Intera Oncology, INC | $31.17 | 2025 | Intera |
| Kite Pharma, INC. | $25.68 | 2023 | |
| Azurity Pharmaceuticals, INC. | $24.89 | 2025 | Danziten |
| Beone Medicines USA, INC. | $24.28 | 2025 | Tevimbra |
| Aimmune Therapeutics, INC. | $22.44 | 2025 | Zenpep |
| G1 Therapeutics, INC. | $22.02 | 2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $21.21 | 2023 | Empaveli |
| Immunocore Limited | $21.02 | 2025 | Kimmtrak |
| Servier Pharmaceuticals LLC | $19.92 | 2024 | |
| Syndax Pharmaceuticals, INC. | $19.89 | 2025 | |
| Octapharma USA, INC. | $19.28 | 2024 | Octagam Immune Globulin (Human) |
| Pharmaessentia USA Corporation | $19.26 | 2023 | Besremi |
| Myriad Genetic Laboratories, INC. | $18.58 | 2023 | Myrisk |
| Mirati Therapeutics, INC. | $18.52 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $18.52 | 2025 | |
| Kyowa Kirin, INC. | $18.09 | 2023 | Poteligeo |
| Spectrum Pharmaceuticals INC. | $16.53 | 2024 | Rolvedon |
| Melinta Therapeutics, LLC | $16.28 | 2024 | Kimyrsa, Rezzayo |
| Pharmacosmos Therapeutics INC. | $15.97 | 2024 | Cosela |
| Morphosys, US INC. | $14.83 | 2024 | Monjuvi |
| Sumitomo Pharma America, INC. | $14.26 | 2024 | Orgovyx |
| Pharmaand Gmbh | $11.77 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Busayavalasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.